PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas

Nature Medicine

Volumn 18, Issue 11, 2012, Pages 1699-1704

  Laimer, Daniela ^a   Dolznig, Helmut ^a   Kollmann, Karoline ^b   Vesely, Paul W ^c,p   Schlederer, Michaela ^d   Merkel, Olaf ^e,q   Schiefer, Ana Iris ^a   Hassler, Melanie R ^a   Heider, Susi ^a   Amenitsch, Lena ^a   Thallinger, Christiane ^a   Staber, Philipp B ^c,f   Simonitsch Klupp, Ingrid ^a   Artaker, Matthias ^g   Lagger, Sabine ^g,r   Turner, Suzanne D ^h   Pileri, Stefano ⁱ   Piccaluga, Pier Paolo ⁱ   Valent, Peter ^a,j   Messana, Katia ^k   Landra, Indira ^k   Weichhart, Thomas ^a   Knapp, Sylvia ^a,l   Shehata, Medhat ^a   Todaro, Maria ^k   Sexl, Veronika ^b   Höfler, Gerald ^c   Piva, Roberto ^k,m   Medico, Enzo ^k,n   Ruggeri, Bruce A ^o   Cheng, Mangeng ^o   Eferl, Robert ^d   Egger, Gerda ^a   Penninger, Josef M ^l   Jaeger, Ulrich ^a   Moriggl, Richard ^d   Inghirami, Giorgio ^k   Kenner, Lukas ^a,d   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f HARVARD STEM CELL INSTITUTE   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^k UNIVERSITY OF TURIN   (Italy)

^l ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^m NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ CANDIOLO CANCER INSTITUTE   (Italy)

^o CEPHALON INC   (United States)

^p SCRIPPS RESEARCH INSTITUTE   (United States)

^q GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^r UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CEP 28122; CRIZOTINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; NUCLEOPHOSMIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN C JUN; PROTEIN KINASE B; RECEPTOR BLOCKING AGENT; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL SURVIVAL; DRUG MECHANISM; ENZYME INHIBITION; HELA CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ADULT; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NUCLEAR PROTEINS; ONCOGENE PROTEIN P65(GAG-JUN); PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSCRIPTION FACTOR AP-1; TRANSLOCATION, GENETIC;

MUS MUSCULUS;

EID: 84869221316     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2966     Document Type: Article

References (40)

1. Kadin, M.E. Ki-1/CD30+ (anaplastic) large-cell lymphoma: Maturation of a clinicopathologic entity with prospects of effective therapy. J. Clin. Oncol. 12, 884-887 (1994 (Pubitemid 24145312)
2. Kadin, M.E. Primary Ki-1-positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity. Ann. Oncol. 5 (suppl. 1), 25-30 (1994 (Pubitemid 24051311)
3. Stein, H. et al. CD30+ anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 96, 3681-3695 (2000
4. Morris, S.W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994 (Pubitemid 24107549)
5. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008
6. George, R.E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008
7. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008
8. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 448, 561-566 (2007 (Pubitemid 47206930)
9. Gambacorti-Passerini, C., Messa, C. & Pogliani, E.M. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364, 775-776 (2011
10. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010
11. Choi, Y.L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010
12. Mathas, S. et al. Aberrantly expressed c-JUN and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB. EMBO J. 21, 4104-4113 (2002 (Pubitemid 34857442)
13. Staber, P.B. et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 110, 3374-3383 (2007 (Pubitemid 350106332)
14. Chiarle, R. et al. NPM-ALK transgenic mice spontaneously develop T cell lymphomas and plasma cell tumors. Blood 101, 1919-1927 (2003 (Pubitemid 36237594)
15. Kent, W.J. et al. The human genome browser at UCSC. Genome Res. 12, 996-1006 (2002
16. Cartharius, K. et al. MatInspector and beyond: Promoter analysis based on transcription factor binding sites. Bioinformatics 21, 2933-2942 (2005 (Pubitemid 40916416)
17. The ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9, e1001046 (2011
18. Andrae, J., Gallini, R. & Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22, 1276-1312 (2008 (Pubitemid 351717519)
19. Claesson-Welsh, L. Signal transduction by the PDGF receptors. Prog. Growth Factor Res. 5, 37-54 (1994
20. Nissen, L.J. et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 117, 2766-2777 (2007 (Pubitemid 47529608)
21. Pardanani, A. & Tefferi, A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104, 1931-1939 (2004 (Pubitemid 39297841)
22. Ergin, M. et al. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp. Hematol. 29, 1082-1090 (2001 (Pubitemid 32780999)
23. Gunby, R.H. et al. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J. Med. Chem. 49, 5759-5768 (2006 (Pubitemid 44423712)
24. Hantschel, O., Rix, U. & Superti-Furga, G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 49, 615-619 (2008 (Pubitemid 351517198)
25. Stover, E.H. et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRB and FIP1L1-PDGFR-α in vitro and in vivo. Blood 106, 3206-3213 (2005 (Pubitemid 41565920)
26. Qiu, L. et al. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108, 2407-2415 (2006 (Pubitemid 44497526)
27. Savan, R. et al. A novel role for IL-22R1 as a driver of inflammation. Blood 117, 575-584 (2011
28. Pietras, K. et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62, 5476-5484 (2002
29. Sumida, T. et al. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Int. J. Cancer 128, 2050-2062 (2011
30. Cheng, M. et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 11, 670-679 (2012
31. Iqbal, J. et al. Molecular signatures to improve diagnosis in peripheral T cell lymphoma and prognostication in angioimmunoblastic T cell lymphoma. Blood 115, 1026-1036 (2010
32. Piccaluga, P.P. et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. 117, 823-834 (2007 (Pubitemid 46348541)
33. Eckerle, S. et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: Insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 23, 2129-2138 (2009
34. Piva, R. et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T cell neoplasms. J. Clin. Oncol. 28, 1583-1590 (2010
35. Wolfer, A. et al. Inactivation of Notch1 in immature thymocytes does not perturb CD4 or CD8 T cell development. Nat. Immunol. 2, 235-241 (2001 (Pubitemid 33706000)
36. Behrens, A. et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J. 21, 1782-1790 (2002 (Pubitemid 34614634)
37. Kenner, L. et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J. Cell Biol. 164, 613-623 (2004 (Pubitemid 38233322)
38. Ovcharenko, I., Nobrega, M.A., Loots, G.G. & Stubbs, L. ECR Browser: A tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res. 32, W280-W286 (2004 (Pubitemid 38997344)
39. Gal-Yam, E.N. et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl. Acad. Sci. USA 105, 12979-12984 (2008
40. Pflegerl, P. et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc. Natl. Acad. Sci. USA 106, 20423-20428 (2009